Mayne Pharma Group Limited (MYX.AX)

4.9800 -0.1300 (-2.54%) 收市：04:10PM AEST

Mayne Pharma Group Limited

1538 Main North Road
Salisbury South, SA 5106
Australia
61 8 8209 2666
https://www.maynepharma.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Shawn Patrick O'Brien B.Sc	CEO, MD & Director	1.27M	無	1959
Mr. Aaron Gray	Chief Financial Officer	1.06M	無	無
Ms. Kimberly Parker J.D.	Executive VP & General Counsel	無	無	無
Mr. Brant Schofield	Executive Vice President of Corporate Development	1.04M	無	1966
Ms. Erinn Nathaniel	Director of Global Human Resources	無	無	無
Mr. Daniel Moore	Executive Vice President of Commercial	無	無	無
Dr. Frank Casty M.D.	Executive VP & Global Chief Medical Officer	無	無	無
Mr. Brenton Walter	Financial Controller	無	無	無
Ms. Laura Loftus	Associate General Counsel & Company Secretary	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 AUD。

描述

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

公司管治

截至 2024年5月1日 止，Mayne Pharma Group Limited 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：5；董事會：2；股東權利：7；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。